Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma

BackgroundImmune checkpoint inhibitor (ICI)-associated cardiotoxicity is a relatively uncommon immune-related adverse effects (irAEs) with a high mortality rate. There are few recommendations for the replacement of different immune checkpoint inhibitors in domestic and international reports.Case pre...

Full description

Bibliographic Details
Main Authors: Tong Wu, Yujun Li, Xiaonan Cui, Chunxia Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
tislelizumab
cardiotoxicity
sugemalimab
PD-L1 inhibitor
squamous NSCLC
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1243980/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1243980/full

Similar Items